Search NLS News

Danish and Swedish life science strategies under the lens at Medicon Valley Alliance Annual Meeting.

During the World AMR Awareness Week (WAAW) NLS has chosen to highlight different Nordic companies and investors sharing what part of the solution they bring to the table and how their impact can be leveraged globally.

BICO has entered into an agreement to divest Nanoscribe to LAB14 GmbH to an equity value of EUR 26 million.

During the World AMR Awareness Week (WAAW) NLS has chosen to highlight different Nordic companies and investors sharing what part of the solution they bring to the table and how their impact can be leveraged globally.

During the World AMR Awareness Week (WAAW) NLS has chosen to highlight different Nordic companies and investors sharing what part of the solution they bring to the table and how their impact can be leveraged globally. 

The company has also announced a reduction in workforce and management layers to improve efficiency and reduce costs.

All over the Nordics, the innovative power is gearing up to put new products, therapies and preventive measures on the market that all help tackle AMR from various angles. 

Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for Xbrane´s Nivolumab Biosimilar candidate (referencing Opdivo).

Modus Therapeutics has received approval from the relevant authorities in Italy for its planned Phase IIa clinical trial with sevuparin.

In the cross-border region Medicon Valley, a new alliance is forming to highlight not just the global challenge that antimicrobial resistance (AMR) poses but the range of solutions being developed in the life science sector.